AVT04: Complete Response Letter
A complete response letter is FDA's decision not to approve an application as submitted. See BLA 761343's history or Alvotech USA's company page.
On Oct 11, 2023, FDA declined to approve AVT04 (BLA 761343) from Alvotech USA Inc. in its present form, citing facility inspections, product quality, microbial quality. The application was later approved.
- Letter date: Oct 11, 2023
- Application: BLA 761343
- Since then: Approved
What FDA Cited
FDA's own section headings in the letter; each finds other letters citing itThe Letter
Text from openFDAFollowing inspection of Alvotech hf, Reykjavik, Iceland (FEI: 3013702557) listed in this application, FDA conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before this application may be appr...… openFDA did not return the full text just now. Open it in the letter search.
Alvotech USA's Other Letters
Newest firstRecord
- Company
- Alvotech USA Inc.
- Application
- BLA 761343
- Status in openFDA
- Approved
- Review division
- Division of Dermatology and Dentistry
FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters